Ricardo Alvarez, Medical Director of the Breast Cancer Center & Director of Cancer Research, Cancer Treatment Centers of America (CTCA), Atlanta, GA, US, talks to touchONCOLOGY about the mutational landscape of metastatic cancers discovered from prospective clinical sequencing at a community practice cancer programme and the findings from the data he presented at ESMO 2018 in Munich, Germany. Dr Alvarez also discusses which type of patients are ideal candidates for next generation sequencing, and he highlights some of the limitations of precision medicine. Finally, Dr Alvarez gives us his throughs on the future of precision medicine and how this translate to clinical practice.
1. What proportion of cancer patients in your institution are receiving drugs matched to mutations in their tumours? (0:11)
2. Could you tell us a little about the data you are presenting from community practices? (0:48)
3. Which tumours are most amenable to this approach? (1:59)
4. What are the limitations of this approach? (2:43)
5. By how much do you expect the proportion of cancer patients receiving matched treatment to rise in the coming years? (3:42)
Speaker disclosures: Ricardo Alvarez has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018
Share this Video
Related Videos In Breast Cancer
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer. The abstract entitled ‘Ribociclib and […]
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!